1. Home
  2. RVMD vs TCOM Comparison

RVMD vs TCOM Comparison

Compare RVMD & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolution Medicines Inc.

RVMD

Revolution Medicines Inc.

HOLD

Current Price

$187.35

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Logo Trip.com Group Limited

TCOM

Trip.com Group Limited

HOLD

Current Price

$42.77

Market Cap

25.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVMD
TCOM
Founded
2014
1999
Country
United States
Singapore
Employees
883
43574
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Hotels/Resorts
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.1B
25.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RVMD
TCOM
Price
$187.35
$42.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
8
Target Price
$140.84
$78.75
AVG Volume (30 Days)
2.8M
3.8M
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
0.57%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.73
Revenue Next Year
$533.02
$13.00
P/E Ratio
N/A
$9.06
Revenue Growth
N/A
N/A
52 Week Low
$34.00
$38.04
52 Week High
$193.83
$79.00

Technical Indicators

Market Signals
Indicator
RVMD
TCOM
Relative Strength Index (RSI) 66.86 43.85
Support Level $93.39 $38.04
Resistance Level N/A $54.81
Average True Range (ATR) 7.33 1.29
MACD 0.42 0.16
Stochastic Oscillator 79.87 53.77

Price Performance

Historical Comparison
RVMD
TCOM

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

About TCOM Trip.com Group Limited

Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.

Share on Social Networks: